QXT-101

About Qx Therapeutics

Qx Therapeutics is a private, pre-revenue biotech targeting high-mortality lung injuries like ALI and ARDS with its novel MAP3K2/3 inhibition platform. The company's lead asset, QXT-101, has secured FDA Fast Track designation and is in Phase 2 development for Pulmonary Graft Dysfunction (PGD) following lung transplantation, with prior authorization for a trial in severe COVID-19. With a focused pipeline and a mechanism applicable to a wide range of lung insults, Qx aims to address a significant unmet medical need in critical care.

About Qx Therapeutics

Qx Therapeutics is a private, pre-revenue biotech targeting high-mortality lung injuries like ALI and ARDS with its novel MAP3K2/3 inhibition platform. The company's lead asset, QXT-101, has secured FDA Fast Track designation and is in Phase 2 development for Pulmonary Graft Dysfunction (PGD) following lung transplantation, with prior authorization for a trial in severe COVID-19. With a focused pipeline and a mechanism applicable to a wide range of lung insults, Qx aims to address a significant unmet medical need in critical care.

Therapeutic Areas